Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intravenous and Oral Amisulpride in Severe Renal Impairment
NCT04849650Phase 1Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amisulpride in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Acacia Pharma Group Plc. Primary endpoint: Amisulpride plasma exposure (AUC) after a single IV dose at 24 hours. Started Jun 2021; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT04849650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849650.